Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Credit agrmnt [a]
Appointed director
|
|
Athenex, Inc. (ATNX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/18/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 03/20/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 09/16/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/18/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Opinion of Harter Secrest & Emery LLP",
"Underwriting Agreement, by and between the Company and SVB Securities LLC",
"Form of Pre-Funded Warrant",
"Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants BUFFALO, N.Y., August 10, 2022 — Athenex, Inc. , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the shares of common stock, warrants and pre-funded warrants are being offered by Athenex. SVB Securities is acting as sole book-running manager for the offering. The offering is ...",
"Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants BUFFALO, N.Y., August 11, 2022 — Athenex, Inc. , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of its underwritten public offering of 35,333,334 shares of its common stock and accompanying warrants to purchase up to 35,333,334 shares of common stock at a combined public offering price of $0.75 per share and accompanying warrant and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 4,666,666 shares of its common stock and accompanying warrants to purchase up to 4,666,666 shares of common stock at a combined public off..." |
|
| 07/28/2022 |
8-K
| Quarterly results |
| 07/11/2022 |
8-K
| Quarterly results |
| 07/01/2022 |
8-K
| Quarterly results |
| 06/24/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 04/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/29/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/24/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/16/2022 |
8-K
| Asset disposition|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"Financial Statements of the Company as of December 31, 2021 and 2020 and for the fiscal years ended December 31, 2021, 2020, and 2019, Business Section, Management’s Discussion and Analysis of Financial Condition and Results of Operations, and Controls and Procedures Section" |
|
| 02/22/2022 |
8-K
| Quarterly results |
| 02/15/2022 |
8-K
| Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility Buffalo, N.Y., FEBRUARY 15, 2022 - Athenex, Inc., , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of its leasehold interest in a manufacturing facility in Dunkirk, New York, to ImmunityBio, Inc. , for approximately $40 million. “We are pleased with the opportunity to partner with ImmunityBio on the sale of our leasehold at the Dunkirk facility,” said Jeffrey Yordon, Chief Operating Officer, President Athenex Pharmaceutical Division, “They are well positioned to build on the foundation that we established in this state-of-the-art facility, and we look forward to ..." |
|
| 01/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 01/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Purchase Agreement, by and between Athenex, Inc. and ImmunityBio, Inc.",
"Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility Buffalo, N.Y., JANUARY 12, 2022 - Athenex, Inc., , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for ImmunityBio, Inc. to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject to adjustment at closing. Proceeds from the sale will be used to service the Company's debt obligations and for other general corporate purposes.The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022. ..." |
|
| 12/28/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/04/2021 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 10/12/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/03/2021 |
8-K
| Quarterly results |
| 08/20/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
|
|
|